<DOC>
	<DOCNO>NCT01448239</DOCNO>
	<brief_summary>Primary Objective : Injection Site Tolerability Secondary Objectives : - To assess safety profile alirocumab SAR236553 ( REGN727 ) - To assess pharmacokinetic-pharmacodynamic relationship alirocumab SAR236553 ( REGN727 )</brief_summary>
	<brief_title>Injection Site Tolerability , Safety , Pharmacokinetics Pharmacodynamics Study After Single Dose Subcutaneous Treatment Alirocumab SAR236553 ( REGN727 )</brief_title>
	<detailed_description>The total duration study subject 15 week include screen period 3 week .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Serum troponin I level exceed upper laboratory limit normal . Male female subject , 18 65 year inclusive . Body weight 50.0 95.0 kg inclusive male , 40.0 kg 85.0 kg inclusive female , body mass index ( BMI ) 18.0 30.0 kg/mÂ² inclusive . Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) . Normal vital sign 10 minute rest supine position . Normal standard 12lead ECG 10 minute rest supine position . Laboratory parameter within normal range , unless Investigator considers abnormality clinically irrelevant healthy subject If female , subject must use double contraception method , except sterilize 3 month postmenopausal . Serum LDLC level &gt; 100 mg/dL screen visit . Exclusion criterion : Subjects indicate use statins accord criterion National Cholesterol Education Program adult treatment panel III Guidelines , updated 2004 ( see Appendix C ) . Initiation new diet major change previous diet within 4 week prior Screening ( Day 21 2 ) . Subjects must willing maintain consistent diet duration study . Use medication nutraceutical order alter serum lipid within 4 week prior screen ( Day 21 2 ) , include limited statin , ezetimibe , fibrates , niacin , omega3 fatty acid , bile acid resin . Fasting serum triglyceride &gt; 200 mg/dL measure 8 12 hour fast . History hypersensitivity reaction doxycycline similar compound . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>